Community-Acquired Bacterial Pneumonia (CABP) - Epidemiology Forecast - 2032

DelveInsight’s "Community-Acquired Bacterial Pneumonia (CABP) —2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Community-Acquired Bacterial Pneumonia Disease Understanding

Community-Acquired Bacterial Pneumonia (CABP) is a common, acute, severe infection of the lung parenchyma. It is a major cause of mortality in adults. It is one of the most frequent respiratory illnesses among various infections triggering sepsis. The Global Burden of Disease Study identified lower respiratory tract infection (LRTI) as the second most common cause of death and years of life lost. Microbiologically, bacteria are common agents in pneumonia, with Streptococcus pneumoniae being the most common cause worldwide.

Streptococcus pneumoniae is a bacteria most often responsible for Community-acquired pneumonia (CAP) in adults worldwide. Some other common bacteria that cause Community-acquired pneumonia (CABP) are Haemophilus influenza and Mycoplasma pneumoniae.

Pneumonia caused by chlamydia and mycoplasma is often clinically indistinguishable from other pneumonia.

Symptoms of Community-Acquired Bacterial Pneumonia (CABP) include malaise, chills, rigor, fever, cough, dyspnea, and chest pain. Cough typically is productive in older children and adults and dry in infants, young children, and older adults. Dyspnea usually is mild and exertional and is rarely present at rest. Chest pain is pleuritic and is adjacent to the infected area.

Although the diagnostic criteria for Community-Acquired Pneumonia (CAP)/ Community-Acquired Bacterial Pneumonia (CABP) seem relatively straightforward, making the correct diagnosis can be difficult. A thoughtful history and physical examination with close attention to the actual respiratory rate and core temperature, as well as careful interpretation of chest radiographs, are required. This caution is especially true in the elderly. The clinical diagnosis of Community-Acquired Pneumonia (CAP) is made on the basis of respiratory symptoms such as cough, sputum production, dyspnea, chest pain, signs of fever, and hypoxemia, as well as an infiltrate on chest imaging.

Some antibiotics have been approved, which will expand the treatment options for Community-Acquired Pneumonia (CAP), particularly in patients with primary complications. Common antimicrobials used to treat Community-Acquired Pneumonia (CAP) include macrolides (alone or in combination with β-lactams), amoxicillin (alone or combined with a macrolide), fluoroquinolones, and third-generation cephalosporins combined with a macrolide.

Community- Community-Acquired Bacterial Pneumonia (CABP) Epidemiology

The Community-Acquired Bacterial Pneumonia (CABP) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia epidemiology segmented as Incident Cases of Community-Acquired Bacterial Pneumonia, Incidence of Community-Acquired Bacterial Pneumonia based on Gender, Incidence of Community-Acquired Bacterial Pneumonia based on Severity, Incidence of Community-Acquired Bacterial Pneumonia based on Pathogens, and Incidence of Community-Acquired Bacterial Pneumonia based on Age. The report includes the Incident scenario of Community-Acquired Bacterial Pneumonia in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise-Community-Acquired Bacterial Pneumonia Epidemiology

The epidemiology segment also provides the Community-Acquired Bacterial Pneumonia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total incident population of Community-Acquired Bacterial Pneumonia associated in 7MM countries was estimated to be 6,961,838 cases in 2022 and expected to increase at a CAGR of 0.37% for the study period, i.e., 2019–2032.
As per the estimates, United States has the highest incident population of Community-Acquired Bacterial Pneumonia in 7MM.

Among the EU5 countries, Germany had the highest incident population of Community-Acquired Bacterial Pneumonia. On the other hand Spain had the lowest incident population. In 7MM, Spain had the lowest number of cases, 329,289 cases in 2022.

Scope of the Report
Community-Acquired Bacterial Pneumonia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
Community-Acquired Bacterial Pneumonia Epidemiology Report and Model provides an overview of the risk factors and global trends of Community-acquired bacterial pneumonia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight into the historical and forecasted patient pool of Community-Acquired Bacterial Pneumonia in the seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps recognize the growth opportunities in the 7MM concerning the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Community-Acquired Bacterial Pneumonia
The report provides the segmentation of the Community-Acquired Bacterial Pneumonia epidemiology by incident cases of Community-Acquired Bacterial Pneumonia in 7MM
The report provides the segmentation of the Community-Acquired Bacterial Pneumonia epidemiology by Incident Cases of Community-Acquired Bacterial Pneumonia, Incidence of Community-Acquired Bacterial Pneumonia based on Gender, Incidence of Community-Acquired Bacterial Pneumonia based on Severity, Incidence of Community-Acquired Bacterial Pneumonia based on Pathogens, and Incidence of Community-Acquired Bacterial Pneumonia based on Age in 7MM

Report Highlights
11-year Forecast of Community-Acquired Bacterial Pneumonia epidemiology
7MM Coverage
Incident Cases of Community-Acquired Bacterial Pneumonia
Incidence of Community-Acquired Bacterial Pneumonia based on Gender
Incidence of Community-Acquired Bacterial Pneumonia based on Severity
Incidence of Community-Acquired Bacterial Pneumonia based on Pathogens
Incidence of Community-Acquired Bacterial Pneumonia based on Age

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM concerning the patient population about Community-Acquired Bacterial Pneumonia?
What are the Key Findings of Community-Acquired Bacterial Pneumonia epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021–2032)?
What would be the total number of patients with Community-Acquired Bacterial Pneumonia across the 7MM during the forecast period (2021–2032)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021–2032)?
At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021–2032)?
What are the disease risk, burden, and unmet needs of Community-Acquired Bacterial Pneumonia?
What are the currently available treatments for Community-Acquired Bacterial Pneumonia?

Reasons to buy

The Community-Acquired Bacterial Pneumonia Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Community-Acquired Bacterial Pneumonia market
Quantify patient populations in the global Community-Acquired Bacterial Pneumonia market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Community-Acquired Bacterial Pneumonia therapeutics in each of the markets covered
Understand the magnitude of Community-Acquired Bacterial Pneumonia population by its incident cases
Understand the magnitude of Community-Acquired Bacterial Pneumonia population by its clinical manifestation specific cases
The Community-Acquired Bacterial Pneumonia epidemiology report and model was written and developed by Masters and PhD level epidemiologists
The Community-Acquired Bacterial Pneumonia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019–2032